SO-002Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). (2nd July 2019) - Chau, I; Bendell, J; Soriano, A; Arkenau, H; Cultrera, J; Santana-Davila, R; Calvo, E; Tourneau, C Le; Zender, L; Mi, G; Schelman, W; Ferry, D; et al.